Activating mutations in a raf gene are common in driving the formation and maint

Question

Activating mutations in a raf gene are common in driving the formation and maintenance of human melanomas. Drugs that target this hyperactive raf protein are initially effective in combating this cancer. However, in some cases, additional activating mutations in the raf gene occur and the melanoma cells become resistant to the first drug. Two companies are synthesizing secondary drugs to combat this resistant melanoma. Company A has produced a drug that inhibits ras activity, whereas Compnay B has produced a MEK inhibitor. Should you buy stock in Company A or Company B (i.e. which company is likely to have an effective drug for the resistant melanoma)? Explain your choice.

Explanation / Answer

Ras is the first step protein in the activation of the Raf protein pathway. Ras activates Raf, which in turn activates MEK protein. Thus the pathway further continues gene expression.

thus, I would suggest you to invest in Company B. Because it will have a better effect on inhibiting the metastasis. As it acts downstream of the Ras pathway so even if Ras inhibition is not controlled MEK inhibitor will inhibit downstream steps. thus, MEK inhibitor will be a better choice of drug.

Related Questions

Navigate

• Browse (All)
• Browse A
• Subjects

---

---

Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.